REALMENT is a four-year initiative supported by the European Commission designed to enhance the treatment of mental disorders using cutting-edge precision medicine approaches that utilise existing pharmaceutical options. This project positions leading research institutions and the pharmaceutical industry at the cutting edge of mental disorder research.
REALMENT aims to meet its goals by leveraging population-scale Real-World Data (RWD) in combination with Randomized Clinical Trial (RCT) data available to the partners. The project will analyse extensive data from Nordic registries, European biobanks, and eHealth records, including whole genome genotypes (n=1.9 million). This analysis will occur within an EU-wide sustainable framework, employing artificial intelligence and machine learning to create tools for prediction and stratification in the field of precision psychiatry.
Our role in the project focuses on essential communication support. This includes crafting and distributing a project-specific newsletter, managing the project’s website, and organising various dissemination events such as conferences and workshops. We are responsible for the regular production and distribution of a newsletter, which keeps stakeholders including patients, healthcare providers, and researchers, informed about project progress, events, and findings. Moreover, the organisation manages the REALMENT project’s website, which serves as a central hub for up-to-date information on the project’s aims, achievements, and resources, ensuring transparency and engagement.
Learn more about the project here.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 964874
Duration
4 years | 2021-2025
Partners
14
Countries
11
Website: https://www.realment.uio.no/